Picture of Ajanta Pharma logo

AJANTPHARM — Ajanta Pharma News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Indian drugmakers face squeeze in U.S. healthcare market

By Zeba Siddiqui 
    MUMBAI, March 17 (Reuters) - India's small and medium-sized 
generic drugmakers say the threat of tougher rules and higher 
barriers for outsiders in the U.S. healthcare market will force 
many to find a niche or focus their expansion efforts on other 
countries. 
    India supplies nearly a third of medicines sold in the 
United States, the world's largest healthcare market. Cut-price 
generics sold by India's small- and medium-sized drugmakers have 
been critical in bringing down prices there. 
    A more protectionist stance by President Donald Trump, with 
the prospect of import tariffs and the U.S. boosting local drug 
manufacturing, mean the operating environment for smaller 
generic players will get worse, executives at Indian companies 
said. 
    "If the challenges keep increasing, competition will reduce, 
and this could actually increase prices there," said D.G. Shah, 
secretary general of the Indian Pharmaceutical Association, 
which represents 20 large Indian drugmakers. 
    J. Jayaseelan, who owns Nuray Chemicals, a maker of drug 
ingredients, said many Indian firms are reconsidering, or 
putting on hold, U.S. expansion plans. 
    Ajanta Pharma  AJPH.NS  is one such firm. The mid-sized 
generics drug maker said it had no plans to scale up its U.S. 
business and would invest more in Asia and Africa instead. 
    "It's not a major market for us right now ... you've got to 
look at the risk-reward ratio," said Rajeev Agarwal, general 
manager of finance at Ajanta. 
    The risks comes as U.S. revenue growth for these firms is 
falling. U.S. revenues for Indian drugmakers rose 15 percent in 
2016, half the average annual growth rate of 33 percent between 
2011 and 2015, ratings agency ICRA said. It expects the growth 
rate to fall further this year. 
    Consolidation among U.S. drugs distributors and a federal 
investigation into drug pricing have also reduced the pricing 
power of drugsmakers. 
    The U.S. drugs regulator, the Food and Drug Administration, 
has also banned dozens of Indian drug factories from supplying 
the U.S. market following inspections that found inadequate 
quality-control practices. Companies have invested significant 
sums to raise their quality standards. 
    Firms that want to focus on the United States will have to 
increase investment in higher-margin niche therapies, or 
products requiring specialised manufacturing, said Mitanshu 
Shah, senior vice president of finance at Alembic 
Pharmaceuticals  ALEM.NS . 
    "Smaller companies with a few regular products and no 
long-term vision for the United States won't last," Shah said. 
    Even with a vision, the U.S. market is just getting tougher 
for companies to operate in, said Vijay Ramanavarapu, the head 
of the U.S. business of drugmaker Granules India  GRAN.NS . 
    "You have to fight twice as hard today," Ramanavarapu said. 
"It will be harder for new entrants to enter the U.S. market 
unless they are able to find niche areas." 
 
 (Reporting by Zeba Siddiqui in Mumbai) 
 ((zeba.siddiqui@thomsonreuters.com; +91-9769624550; Reuters 
Messaging: zeba.siddiqui.thomsonreuters.com@reuters.net)) 
 
Keywords: INDIA PHARMACEUTICALS/USA

Recent news on Ajanta Pharma

See all news